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Insights into Cyclin Groove Recognition:
Complex Crystal Structures and Inhibitor
Design through Ligand Exchange
functions are commonly altered in tumor cells (Ortega
et al., 2002). Deregulation of CDK2 and CDK4 through
inactivation of CDKIs such as p16INK4a, p21WAF1, p27KIP1,
and p57KIP2 thus provides a means for cancer cells to
override the G1 checkpoint. Reinstatement of CDK inhi-
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cological interference with tumor progression. This isand Peter M. Fischer1
1Cyclacel Ltd. particularly attractive as one consequence of unchecked
CDK2 activity is persistent E2F transcriptional activity,James Lindsay Place
Dundee DD1 5JJ, Scotland which, unless terminated in a timely fashion during
S-phase, constitutes a powerful apoptotic signal (LeesUnited Kingdom
2 AstraZeneca Pharmaceuticals and Weinberg, 1999). Because E2F deactivation occurs
through phosphorylation by CDK2/CA, tumor cells willAlderley Park
Macclesfield be selectively sensitive to inhibition. One method of
CDK2/CA inhibition is through the use of peptides thatCheshire SK10 4TG
United Kingdom block binding of both pRb and E2F to the CDK2/CA
complex (Fischer and Lane, 2000).3 The University of Edinburgh
Michael Swann Building Recognition of both of these substrates, as well as
CDKIs, by the CDK2/CA complex depends on a shallowKing’s Buildings
Edinburgh EH9 3JR, Scotland hydrophobic surface binding site in the cyclin A subunit,
termed the cyclin groove (Schulman et al., 1998). Recog-United Kingdom
nition of this groove is mediated through certain se-
quences, designated the CBM (Chen et al., 1996). This
motif represents a consensus of the cyclin groove bind-Summary
ing sequences found in a variety of CDK2/CA partner
proteins, including the CDKIs, pRb proteins, E2F tran-Inhibition of CDK2/CA (cyclin-dependent kinase 2/cyclin
scription factors, p53, HDM2, the CDK-activating kinaseA complex) activity through blocking of the substrate
CDK7, etc. This sequence is commonly referred to asrecognition site in the cyclin A subunit has been dem-
the RXL or ZRXL motif, where Z and X denote basiconstrated to be an effective method for inducing apo-
residues (Fischer et al., 2003). Following a detailed studyptosis in tumor cells. We have used the cyclin binding
with peptides representing various sequences frommotif (CBM) present in the tumor suppressor proteins
cyclin A binding proteins, we recently refined the defini-p21WAF1 and p27KIP1 as a template to optimize the mini-
tion of the motif (McInnes et al., 2003): ZRXLYY, wheremal sequence necessary for CDK2/CA inhibition. A
Y and Y are hydrophobic residues. The cyclin bindingseries of peptides were prepared, containing nonnatural
motif from p21 has also been examined by anotheramino acids, which possess nano- to micromolar CDK2-
group, which concluded that the motif is more accu-inhibitory activity. Here we present X-ray structures of
rately described as a cluster of hydrophobic residuesthe protein complex CDK2/CA, together with the cyclin
covering the LYY portion of the sequence abovegroove-bound peptides H-Ala-Ala-Abu-Arg-Ser-Leu-
(Wohlschlegel et al., 2001). However, other positions inIle-(p-F-Phe)-NH2 (peptide 1), H-Arg-Arg-Leu-Ile-Phe-
the motif are seen and differences are observed in theNH2 (peptide 2), Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2
relative importance of particular residues, most proba-(peptide 3), H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 (pep-
bly due to differences in experimental design.tide 4), and H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 (peptide 5).
When CBM peptides are conjugated to cellular deliv-Some of the peptide complexes presented here were
ery vectors (Fischer et al., 2001), the resulting peptideobtained through the novel technique of ligand ex-
constructs cause cell cycle arrest and selective apopto-change within protein crystals. This method may find
sis in tumor cells in vitro (Ball et al., 1996; Bonfanti etgeneral application for obtaining complex structures
al., 1997; Chen et al., 1999) and, as shown more recently,of proteins with surface-bound ligands.
in vivo (Mendoza et al., 2003). Inhibition of CDK2 activity
through blocking of substrate recruitment is also likely
Introduction to provide kinase selectivity, which is more difficult to
achieve with traditional ATP-competitive molecules
Human cancer cells are characterized by the loss of cell (Fischer, 2001), since the cyclin-dependent substrate
cycle checkpoint regulation, leading to cell proliferation recognition, and hence phosphorylation, appears to be
under conditions where nontransformed cells cannot unique to CDKs 2 and 4.
enter and pass through the cell cycle. CDKs and their A number of CDK2/CA complex X-ray crystal struc-
natural inhibitors, the CDK tumor suppressor proteins tures with CBM peptides have been reported. The first
(CDKIs), are central to cell cycle regulation and their of these included a 68-residue p27KIP1 fragment con-
taining the 30RNLFG34 sequence (Russo et al., 1996). A
later study used a peptide with the sequence*Correspondence: gkontopidis@cyclacel.com
Structure
1538
658RRLFGEDPPKE668 from p107, a pRb family protein
(Brown et al., 1999). The most recent complexes re-
ported included the peptides 376STSRHKKLMFK386 (p53),
868PPKPLKKLRFD878 (pRb), 25KPSACRNLFGP35 (p27KIP1),
87PVKRRLDLE95 (E2F), and 653AGSAKRRLFGE663 (p107)
(Lowe et al., 2002). Our present work represents the
first report using various peptides with the p21WAF1 motif
155RRLIF159.
In our recent work, comparison of a series of octapep-
tides derived from the p21WAF1 CBM-containing se-
quences, as well as those found in p107, E2F1, and
p27KIP1, showed (Zheleva et al., 2002) that the p21WAF1
155RRLIF159 motif was the most effective in cyclin A in-
hibitor peptides. In this motif the Arg155 residue was
demonstrated to contribute extensively to binding. The
optimized bioactive peptide H-His-Ala-Lys-Arg-Arg-
Leu-Ile-Phe-NH2, a low nanomolar CDK2/CA inhibitor
(Zheleva et al., 2002), corresponds to the p21WAF1(152-
159) sequence, with a Ser153-Ala mutation, which was
found to enhance potency significantly. These observa-
tions rendered this sequence a good candidate for
structural studies, as it provides the best template for
the design of peptidomimetics. Herein we describe our
initial approach toward the development of potent,
smaller, and less peptidic inhibitors of CDK2/CA. We
used the X-ray structures of these p21WAF-derived pep-
tide analogs, several of which were obtained through
“ligand exchange,” in conjunction with in vitro activity
results to provide a comprehensive description of the
requirements of each position in the CBM and to define
a series of design principles for the structure-guided
design of small molecule cyclin groove inhibitors.
Figure 1. Ribbon Representation of the Noncrystallographic Dimer
of the Ternary CDK2/CA/peptide 2 Complex
CDK2 molecules are shown in black, cyclin A subunits in pink andResults and Discussion
cyan. Bound peptides are colored green and orange. ATP binding
sites are shown with yellow backbone atoms.In our previous work, we delineated the components of
the p21WAF1 CBM (Zheleva et al., 2002) and arrived at a
complete description of the motif through both exten- tide is replaced by elution, followed by “soaking-in” a
different inhibitor peptide. This approach, which may besive residue replacements, as well as by molecular mod-
eling (McInnes et al., 2003). We proposed that residues of general utility in a variety of structural areas, is also
described.C-terminal to the ZRXL motif are also critical for cyclin
A binding and hence the motif would be better described The peptide residue numbering system used through-
out this work is based on the minimally active pentapep-by the sequence ZRXLYY, where either Y and/or Y are
hydrophobic residues. In this study, we were able to tide sequence, where amino acid residues are denoted
Arg1-Arg2-Leu3-Ile4-Phe5 and residues extending fromconfirm this crystallographically and in addition, found
that the ZRXLYY motif can be further truncated to the N and C termini are numbered 1 and 6, respec-
tively. The cyclin groove components involved in bindingRXLYY, since the pentapeptide H-Arg-Arg-Leu-Ile-Phe-
NH2 retains considerable potency. In the present study, specific residues are denoted similarly, e.g., site 1 for
elements interacting with the residue at position (P1) ofseveral CBM peptides, including those identified pre-
viously (McInnes et al., 2003), containing unnatural the peptide ligand.
amino acids, which resulted in potency enhancements,
were crystallized with CDK2/CA and their interactions Crystal Soaking and Ligand Exchange
Initially, published crystallization conditions (Jeffrey etwith the cyclin groove described. The structural interpre-
tation of the potency differences between various CBM al., 1995) were employed. However, attempts to intro-
duce peptides by soaking of these crystals were notpeptides illustrates the determinants of cyclin groove
binding and shows that small substitutions in the pep- successful and resulted in crystal lattice disorder and
X-ray diffraction at a resolution of 5 A˚ at best. All peptidetide structures can result in profound differences in ac-
tivity and in the bound conformation. complex structures presented here were solved using
a novel crystal form, which has space group P212121 andIn most cases it was not possible to cocrystallize
complexes of the peptides with cyclin A and CDK2. To contains two copies of the binary protein complex in
the crystallographic asymmetric unit. Of the two peptideovercome this problem, we developed the novel tech-
nique of ligand exchange, in which a cocrystallized pep- ligands in this complex, one (red in Figure 1) is fully
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cyclin A molecule in the crystallographic unit is partially
blocked by a neighboring CDK molecule, diffusion of
the peptide ligand to this site was incomplete, even after
3 days of soaking. For this reason, ligand occupancy
levels at the partially occluded binding groove are lower
than at the free site in some of our structures. Due
to this differential occupancy of the two sites in the
asymmetric unit, only the fully accessible cyclin groove
was used to compare the different bound peptide li-
gands. Crystallographic data for several novel p21WAF1-
derived peptide structures are summarized in Table 1.
Crystal-Ligand Exchange as a General Technique
The idea of soaking out ligands and leaving the crystal
lattice intact, ready for reintroducing a new ligand, has
been applied to metals and ions but the technique of
Figure 2. Replacement of One Peptide with Another in the CBG of “ligand exchange” has only rarely been applied to larger
a CDK2/CA Crystal organic molecules (Munshi et al., 1998). Despite consid-
1Fo  1Fc difference electron density maps after 2 days soaking in erable efforts, we were not able to obtain crystals of
mother liquor.
uncomplexed CDK2/CA in the required crystal form and
a ligand exchange protocol was developed that allowed
us to examine a series of peptide complexes.exposed to solvent channels in the crystal, while the
second peptide site is partially occluded. The most common application of crystal-soaking ex-
periments is in the study of enzyme active site inhibitors.Peptides 2 and 4 were cocrystallized with CDK2/CA,
while the remaining peptide complexes were prepared If crystals of the apo-enzyme are available, the tech-
nique of ligand exchange does not provide an obvioususing the following ligand exchange procedure. A crystal
containing H-Arg-Arg-Leu-Ile-Phe-NH2 was soaked ex- advantage over crystal soaking or cocrystallization with
a given inhibitor. For nonenzymatic targets, it is moretensively against precipitant solution to elute the original
peptide. Examination of electron density difference likely that protein recognition sites will be occupied by
neighboring molecules in the crystal lattice. As we showmaps around the cyclin binding groove regions showed
that the original cocrystallized peptide (Figure 3, peptide here, cocrystallization of protein with a ligand, followed
by “ligand exchange,” may provide a more general way2) had indeed been washed out (Figure 2). A second
crystal was treated in the same way and then soaked of studying binding sites involved in protein-protein in-
teractions.in approximately 10 l mother liquor solution containing
1 mM of a different peptide. The structure obtained In general, the time required for ligand-soaking experi-
ments can vary between seconds and days. In systemsshowed that this peptide had been able to diffuse into
the crystal lattice and to dock in the cyclin groove (Figure where no protein rearrangement is necessary (e.g., di-
peptide ligands soaked into crystals of cyclophilin),3, peptides 1, 3, and 5). As the binding groove of one
Figure 3. The Electron Density Maps of Pep-
tides 1–5
The 2Fo  1Fc maps are contoured at a level
corresponding to 1.2 for the peptides bound
to the nonoccluded cyclin groove.
(A) Superimposition of the structures of pep-
tide 2 in the free (yellow) and partially oc-
cluded (green) CBG shows the differences of
the two copies of the peptide.
(B) Overlay of the bound conformations of
peptides 1 (gray), 2 (green), 3 (red), 4 (CPK
coloring), and 5 (magenta).
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Table 1. Crystallographic Data and Statistics
Peptide
1 2 3 4 5
Data Collection
Space group P212121 P212121 P212121 P212121 P212121
Unit cell (A˚)
a 74.5 74.2 74.5 73.5 74.5
b 114.6 113.9 114.0 113.0 113.5
c 157.0 155.3 156.2 153.1 154.5
Max. resolution (A˚) 2.9 2.4 2.5 2.6 2.9
Observations 430,926 563,579 553,149 574,133 648,091
Unique reflections 31,043 52,345 46,855 39,765 29,357
Completeness (%) 84.6 96.7 99.0 99.5 98.9
Rmerge1 0.10 0.11 0.10 0.11 0.12
Mean I/ 8.7 5.9 4.9 5.8 2.8
Highest resolution bin 2.97-2.9 2.46-2.4 2.64-2.5 2.74-2.6 3.06-2.9
Mean I/ (highest resolution bin) 1.4 1.2 1.0 1.0 1.5
Rmerge1 (highest resolution bin) 0.59 0.65 0.47 0.62 0.46
Refinement
Protein atoms 8,924 8,924 8,924 8,924 8,924
Inhibitor atoms 124 100 108 102 102
Water 196 746 539 383 75
Reflections used in refinement 24,032 47,769 44,775 36,002 27,895
Rfactor 19.3 19.7 17.2 19.6 20.2
Rfree 29.2 27.8 25.3 28.9 29.1
Mean B-factor, protein (A˚2) 37.2 36.2 48.1 37.3 50.7
Mean B-factor, ligands (A˚2) 47.5 44.2 54.3 48.5 66.3
Mean B-factor, solvent (A˚2) 29.3 36.7 49.3 40.4 50.7
binding was found to take place within seconds (Wu et the groove form a number of subsites including the LYY
hydrophobic pocket (Met210, Ile213, Leu214, Trp217, Leu253),al., 2001). This contrasts with soaking times of days
required for the binding of some CDK2 active site inhibi- the arginine site (RX; Glu220), and a secondary lipophilic
pocket we call the alanine pocket (Val221, Ile281). In addi-tors, which require significant changes in the protein
conformation before binding can occur (Wu et al., 2003). tion, binding is also facilitated by a number of H bond
interactions with the peptide backbone, including a pairDiffusion of peptides in and out of the CDK2/CA crystals
was slow and in some cases, even after a period of 3 of interactions with the side chain carboxamide of Gln254.
Despite the well-documented observation that the CDK2days of soaking in new peptide solution, the original
peptide could still be observed to occupy the binding kinase subunit of the CDK2/CA complex undergoes sig-
nificant conformational changes upon cyclin bindinggroove. However, occasional agitation of the crystalliza-
tion mixture during the 3-day period led to complete and T loop phosphorylation, the cyclin subunit structure
is essentially the same in the free and complexed formsligand exchange. Solution studies for peptides binding
to the CBG using a competitive binding assay (McInnes (Brown et al., 1995). In our peptide complex structures,
most of the cyclin A binding groove (CBG) atoms areet al., 2003) demonstrated that equilibrium is reached
within a few seconds. Buffer and salt conditions in these rigid and their average B factors do not change upon
ligand binding. This was confirmed by comparison ofsolution studies and in the crystal exchange experi-
ments described here were very similar, apart from the the temperature factors of the CBG atoms with the rest
of the cyclin A chain, as well as by comparison of thehigh PEG concentrations in the crystal soaking experi-
ments. It therefore seems that diffusion rates play a unliganded and peptide-liganded CDK2/CA structures.
All main chain atoms of the residues in the groove havemajor role during ligand exchange in crystals. It was
fortuitous that the crystal system described has two low B factors in both the peptide-bound and unliganded
structures, although there are some significant differ-ligand binding sites with different crystallographic envi-
ronments, allowing us to obtain unambiguous results ences in the side chains of the hydrophilic residues of
the binding groove.for the accessible site. Our results with this cyclin-CDK2
system suggest that the ligand exchange approach may All residues in all of the peptide ligands complexes
presented here are well defined by electron density.be of general use in different protein systems where
native protein crystals are not readily obtainable. The electron density difference maps of the peptide
complexes are shown in Figure 3. As mentioned, two
CDK2/CA complexes exist in the asymmetric unit of ourOverall Interactions between Ligand
crystal form. The differences between the two copiesPeptides and Cyclin A
of peptide 2 structures bound in the different CBGs areThe binding site for the CBM peptides is comprised of
illustrated in Figure 3A. The RMS deviation for all atomsa shallow groove resulting from the exposed surface of
the cyclin A 1, 3, and 4 helices. The residues lining (50) after superimposition was 0.163 A˚. Arg1, Leu3, and
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Phe5 make similar contacts in both cases, with some contacts between Glu220 and the Cit-containing peptide.
A similar picture emerges from comparison of the aver-variation for Arg2. These variations should be considered
in the context of the flexible Glu220 receptor side chain age cyclin A Glu220 side chain atom B factors in both the
peptide 5 and peptide 2 complex structures. In the latterand are discussed in more detail below. Ile4 does not
make contact with the binding groove and is restrained structure, this factor lies only 20.5% above the average
for all main chain atoms, whereas, in the unliganded andonly through intramolecular contacts with Arg2. Arg2 it-
self participates in charge-charge interactions with peptide 5-liganded complexes, the value rises to 45%
and 67%, respectively. This is a clear indication of largecyclin A, as well as some weak contacts with the neigh-
boring CDK2 molecules in the case of the partially oc- displacement of Glu220 side chain atoms when peptide
5 binds in the CBG.cluded CBG.
An overlay of all the solved peptide structures is Another factor contributing to the decrease in activity
is the loss of intramolecular contacts with Leu3. Theshown in Figure 3B. Although the peptides bind in super-
ficially similar modes, significant differences in inhibitory peptide 5 2Fo  1Fc map shows an absence of density
for the Leu3 side chain beyond the C atom, indicatingpotency, and hence binding affinity, were observed be-
tween the peptides. These differences can be explained free rotation about the C-C bond. By contrast, all
atoms of the Leu3 side chain are clearly visible in theafter detailed examination of the specific interactions
formed or lost in each case, and are summarized below. electron density difference maps for the peptide 2 and
peptide 4 structures (Figure 3). Apart from these differ-
ences at P1 and P3, the positions of the remaining atoms
Peptide Potency and Design are similar, including the P5 side chain conformation.
Analysis of peptide 2 complexed with cyclin A shows The effect of acetylation of the N-terminal nitrogen
that the bound conformation is stabilized through a was also investigated. In the peptide 2 complex struc-
number of contacts with the CBG, involving the side ture, the peptide amino terminus forms an H bond (3 A˚)
chains of Arg1, Leu3, and Phe5, as well as the peptide with the carbonyl of Ile281 and a similar H bond is also
backbone (Figure 4A). The latter include the Arg1 termi- observed in peptide 4 and peptide 3 structures. The
nal NH2, Arg1 CO, and Leu3 NH groups. Judging from weakening of this H bond (3.4 A˚) upon acetylation of
the interatomic distances, however, none of these form the peptide N terminus is consistent with the reduced
strong H bonds. Additionally, a number of intramolecular biological activity of acetylated peptides (Table 2). An
interactions involving Arg1, Leu3, and Phe5 are observed. additional interesting observation relating to this in-
It is clear from the peptide crystal structures that resi- volves the Arg1 side chain, which cannot make the same
dues P1, P3, and P5 will be the main potency determi- contacts in the acetylated and nonacetylated peptides.
nants, while P2 and P4, whose side chains project away In the acetylated peptide, a series of contacts are ob-
from the binding groove, will be less important. Further- served that are absent in peptides with free N termini
more, the P1, P3, and P5 side chains appear to form an and involve the acetyl O, a water molecule, the Glu220
intramolecular network of interactions. Thus, the side side chain, as well as the NH group of the Arg1 side
chains of Arg1 and Phe5 interact with the cyclin groove chain.
in such a way as to trap between them the Leu3 side P 2 Site
chain (Figure 4B1). The relative contribution to binding Analysis of the peptide activity data for different amino
of each residue in the peptides can be judged from the acid residues in this position suggests that it is compara-
activity summary in Table 2. It should be kept in mind tively tolerant of modification. This finding is supported
when analyzing the potency data that the effect of any by the complex structures, which do not show any
one mutation will be more profound in the context of a strong interactions between the P2 side chain and the
shorter than of a longer peptide. protein. In contrast to P1, replacement of the charged
P1 Site side chain at P2 has comparatively little effect on biologi-
A key interaction in the CBM, and a requirement for cal activity, as is apparent from the Arg2-Cit mutation.
good inhibitory potency of relevant peptides, is the ion Inclusion of certain uncharged residues at P2 is also
pair between Glu220 and Arg1. The importance of Arg in tolerated to some extent, e.g., Gln (Table 2) or Ser (McIn-
this position was also borne out in previous structures nes et al., 2003). The observed 3-fold reduction in po-
(Lowe et al., 2002), and mutation of Arg1 always results tency, however, is consistent with the decrease in the
in a decrease in biochemical inhibitory activity (McInnes Coulombic interaction energies calculated upon substi-
et al., 2003). Even the isosteric substitution of Arg1 with tution of the Arg2 with Asn.
Cit1, i.e., replacement of the guanidine –NHCNH(NH2) P 3 Site
with an urea –NHCO(NH2), leads to a significant de- The necessity of a hydrophobic side chain at this posi-
crease in potency. Replacement of the  imino function tion, as indicated by the activity data, is obvious from
in Arg with the carbonyl group in Cit results in a system all structures reported here. The Leu3 side chain partici-
with similar H bonding ability, but, unlike the Arg guani- pates in a network of van der Waals contacts with Gln254,
dine, the Cit urea is not charged under physiological Trp217, and Leu214 of cyclin A, in addition to several intra-
conditions and therefore does not participate in ion pair molecular contacts with P1 and P5 (Figures 4B and 4C).
interactions. Analysis of the peptide 5 complex crystal Inspection of the complex structures and molecular
structure shows that the distance between Cit1 NH and modeling suggest that the Leu side chain is the optimum
the Glu220 side chain carbonyl O is 5.1 A˚, whereas the size for this position. Mutation of Ile is tolerated, but
corresponding distance in the peptide 4 structure is results in bad contacts and mutation to Ala leads to
significant loss of potency. The Leu3 side chain forms4.5 A˚. This difference effectively results in loss of the
Structure
1542
Figure 4. Inter and Intramolecular Interactions of Peptides 2, 3, 4, and 5
(A) H bonds involving the backbone of peptide 2.
(B) Effect of P1 side chains: A charged P1 side chain affects the position and flexibility of the Leu3 side chain through van der Waal contacts,
effectively locking the Leu3 side chain between side chains P1 and P5. Mutation at P1 from Arg (B1) to Cit (B2) results in a more flexible side
chain at P1, leading to a removal of the Leu3 lock, whose side chain is now more flexible (refer Figure 3, electron density map 5).
(C) Contacts of the Leu3 side chain in the peptide 2 structure.
(D) Superimposition of the cyclin A-bound H-Arg-Arg-Leu-Ile-Phe-NH2 (CPK coloring) peptide and the corresponding p27KIP1 peptide segment
30Arg-Asn-Leu-Phe-Gly34 (magenta; PDB accession code 1JSU).
(E) Van der Waals surfaces of the Ac-Arg-Arg-Asn-(m-Cl-Phe)-NH2 (green) and peptide 4 (red) complex structures surrounding the Phe5 site.
The fluorine and chlorine surfaces match exactly at the interface with the cyclin A surface.
the core of the binding surface for all of the peptides make more complementary contacts with the hydropho-
bic pocket (Figure 4D). Also, as is discussed in the fol-investigated and a residue with a side chain of lesser
bulk in this position would allow the side chains at P1 and lowing section, the linker residue allows a more favor-
able intramolecular peptide conformation of the Leu3P5 to move freely. This in turn would result in disruption of
the bound conformation, similar to the effect described and Phe5 residues. In addition, the Ile4 spacing residue
allows the P3 carbonyl in peptide 2 to form a strongabove for P1, but with a more profound result since now
both neighboring side chains and their protein contacts water-mediated H bond (2.4 A˚) with the Gln254 side chain
(Figure 4). In contrast, this carbonyl in the p27KIP1 com-would be affected.
P 4 Site plex structure is rotated by almost 180	 (Figure 4) and
consequently this H bond is not present. These observa-The major role of this residue (as encountered in the
p21WAF1 and p53 CBMs) is to act as a linker between the tions are backed up by the biochemical data since re-
moval of Ile3 results in 12-fold lower potency (Table 2).P3 and P5 hydrophobic groups. Incorporation of a linker
is favorable for binding and in the peptides tested im- Furthermore, comparison of the structural data confirms
that, due to the different conformations of the Phe5 sideproves potency relative to the p27KIP1 CBM, where the
P4 residue is absent (Leu3-Phe5-Gly6). The extra three chain, the p-F-Phe phenyl ring substitution is less effec-
tive in the context of the Leu-Phe-Gly sequence; theatoms of the Ile4 residue in the backbone structure allow
P5 to adopt a more favorable position in the groove and same modification of the aromatic side chain of Phe5
Cyclin Groove Recognition
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Table 2. Peptide Structure-Activity Relationships Summary
IC50 (M)
Modifications Competitive Cyclin A CDK2/Cyclin A
at Position Sequence Binding Kinase Activity
1 Ac-Arg-Arg-Leu-Asn-( p-F-Phe)-NH2 2.0 12
H-Arg-Arg-Leu-Asn-( p-F-Phe)-NH2 0.53 7.2
H-Arg-Cit-Leu-Ile-( p-F-Phe)-NH2 0.59 0.52
H-Cit-Cit-Leu-Ile-( p-F-Phe)-NH2* 21 37
2 H-Arg-Arg-Leu-Ala-( p-F-Phe)-NH2 0.73 8.1
H-Arg-Cit-Leu-Ala-( p-F-Phe)-NH2 2.6 24
H-Arg-Gln-Leu-Ile-( p-F-Phe)-NH2 24 8.3
H-Arg-Cit-Leu-Ile-( p-F-Phe)-NH2 0.59 0.52
3 H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH2 0.05 0.14
H-His-Ala-Lys-Arg-Arg-Ala-Ile-Phe-NH2 1.5 
50
4 H-Cit-Cit-Leu-Ile-( p-F-Phe)-NH2* 21 37
H-Cit-Cit-Leu-Ala-( p-F-Phe)-NH2 79 12
H-Cit-Cit-Leu-Asn-( p-F-Phe)-NH2 19 37
H-Arg-Arg-Leu-Ile-Phe-NH2* 0.68 7.7
H-Arg-Arg-Leu- — -Phe-NH2 8.1 
50
H-Arg-Arg-Leu-Asn-( p-F-Phe)-NH2 0.53 7.2
H-Arg-Arg-Leu- — -( p-F-Phe)-NH2 19 50
5 Ac-Arg-Arg-Leu-Asn-Phe-NH2 12 
50
Ac-Arg-Arg-Leu-Asn-( p-F-Phe)-NH2 2.0 12
Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2* 5.6 31
Ac-Arg-Arg-Leu-Asn-( p-Cl-Phe)-NH2 1.8 13
*Peptides with CDK2/CA complex structures.
results in considerable potency gains in the Leu-X-Phe (p27KIP1; PDB, 1H27) peptide (Lowe et al., 2002) (Table
3). The results help to explain the individual contribu-motif (Table 2). In all of the structures reported here, the
P4 side chain does not make any contacts with cyclin tions for the p21WAF1 and p27KIP1 CBM peptides in terms
of binding energy and indicate that a major contributionA. Despite this observation, peptide potency does de-
pend to some extent on the nature of P4. A -substituted to the observed difference in affinity is due to the pres-
ence of a second charged Arg at P2 in p21WAF1. Althoughside chain is preferred, presumably as it favorably re-
duces peptide flexibility in the unbound state. this residue does not appear to make specific protein
contacts, it does contribute significantly via CoulombicP 5 Site
This site was probed with a variety of residues leading energy due to its proximity with Asp283. In addition, there
also appears to be considerable contribution to bindingto the conclusion that certain aromatic side chains are
optimal (McInnes et al., 2003). The most potent Phe from the surrounding solvent-mediated H bonds. Whereas
the p27KIP1 peptide structure (Russo et al., 1996) containsderivatives were found to be para substituted (Table 2).
The crystal structures of three peptides in which P5 is a single water molecule interacting with the peptide, we
refined our structures to include as many crystallograph-m-Cl-Phe or p-F-Phe in complex with the cyclin A groove
demonstrate that P5 always occupies the same site (Fig- ically defined water molecules as could be found, espe-
cially in the binding groove, for the purpose of usingure 4E). The P5 side chain in peptide 3 adopts a different
conformation to that in the other structures (Figure 4B). these in drug design. Specifically, the energetic analysis
suggests that a water-mediated H bond from the Leu3Here the meta-chloro group forces the Phe5 ring into a
different conformation. As a consequence, it forms bad carbonyl to the Gln254 side chain provides 14 kcal/mol
to the binding energy of the p21WAF1 sequence. We alsocontacts with Met210; these are offset, however, by the
more favorable interactions of the chloro group with the carried out energy minimization calculations on the
bound conformations for peptide 2 and the H-Arg-Arg-base of the lipophilic pocket. The observed contacts
with this pocket are so specific that the chlorine and Leu-Phe-NH2 peptide in isolation from cyclin A. The en-
ergy difference between the minimized peptide confor-fluorine van der Waals surfaces coincide very closely in
the two superimposed peptide structures, despite the mation and that observed when bound to the CBG is
an indication of the energetic penalty a peptide has todiffering positions of the aromatic rings (Figure 4E). This
observation reinforces the optimal substitution position pay during binding. Since peptide 2 has to form nonopti-
mal intramolecular contacts and torsion angles in orderof the P5 phenyl ring as being para, a result reflected
by the peptide activity data (Table 2). to form complementarity with the cyclin groove, there
is an unfavorable enthalpic contribution to the overall
free energy. This was shown from the observation thatComputational Analysis
In an attempt to better understand the observed differ- the energy difference between the bound and minimized
bound peptides was much greater for the p27KIP1 (54ences in affinity for p21WAF1- versus p27KIP1-derived CBM
peptides, intermolecular nonbonded energetics were kcal/mol) versus the p21WAF1 sequence (17 kcal/mol). As
the binding energetics are comparable for peptide 2 andcalculated using the X-ray complex structures of the
peptide 2 (p21WAF1) and H-Arg-Asn-Leu-Phe-Gly-OH 4 H-Arg-Arg Leu-Phe-NH2, this factor most likely explains
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Table 3. Comparison of Binding Energies and Torsion Angles of p21WAF1- and p27KIP1-Derived CBM Peptides
Interaction Energy (kcal/mol) Torsion Angle (	)
Peptide 1 2 3 Angle Ideal Values p21WAF1Ile4 p21WAF1Phe5 p27KIP1Leu3 p27KIP1Phe4
Coulombic 323 122 286  65.3 52 86
Van der Waals 59 59 59 1 64.1 72 38
Total (cyclin A  383 181 345 2 177 134 81
peptide)
Total (solvated cyclin 410 194 356  180 178 — 171 —
A  peptide)
H2O-bridged H bond* 14
Individual residues
P1 107 104 104
P2 66 5.5 50
P3 7.4 4.3 4.7
P4 0.40 12 12
P5 11 1.1 1.5
P6 (Pro) 36
Peptides: (1) H-Arg-Arg-Leu-Ile-Phe-NH2; (2) H-Arg-Asn-Leu-Phe-Gly-OH; (3) H-Arg-Arg-Leu-Phe-NH2.
*Water-bridged H bond between the peptide Leu3 (CO) and Gln254 side chain (Fig. 4a) present only in p21WAF1 motif.
the more than 10-fold potency decrease for the latter not available in the pentapeptides. A second charged
residue present at P2 in CBMs can be eliminated morepeptide. Those two peptides adopt a very similar confor-
mation for the first three residues up to Leu3 (Figure 4D). readily, due to the lesser contribution to binding. Al-
though the side chain of Arg2 does not form direct con-The main differences between the bound conformations
are observed after Leu3. These differences are the result tacts with the cyclin groove, it clearly participates in
long-range electrostatic interactions. Arg at P2 can beof nonideal values for the intramolecular contacts in the
p27KIP1 versus the p21WAF1 bound peptides, which also effectively replaced, e.g., with Cit or Gln, and with other
residues capable of both donating and accepting Hreflects the less favorable , 1, 2, and  torsion angles
of Leu3 and Phe4 for the p27KIP1 peptide (Table 3). While bonds. The Leu residue at P3 is invariant in all known
CBMs and our results confirm that the Leu side chainthese energetic calculations are obviously approximate,
they nonetheless provide insight into the potency differ- optimally occupies the hydrophobic pocket at that site.
The P4 residue serves predominantly as a linker and aences between cyclin groove inhibitor peptides.
steric constraint. As it does not form any direct interac-
tions with the protein, it is a potential candidate forConclusion
modifications designed to improve the physicochemicalThe technique of ligand exchange was shown here to
characteristics of future inhibitors. Finally, P5 is prefera-be an effective way of obtaining crystallographic infor-
bly an aromatic residue with a halogen-substituted phe-mation on series of compounds without having to de-
nyl group. The crystal structures and potency data indi-pend on successful cocrystallization. As has been high-
cate that occupying the volume filled by the halogenlighted, many proteins do not yield crystals in the
atoms makes important contributions to binding andabsence of suitable ligands. In the case studied, the use
hence should be accounted for in ligand design. Molecu-of a suitable starting ligand allowed the formation of
lar modeling shows that there is sufficient space aroundcrystals, which were subsequently employed to provide
this ring in the hydrophobic groove pocket to accommo-structural information for numerous ligands. The results
date additional substituents, which could further in-reported here suggest that the ligand exchange ap-
crease the buried surface and hence the potency.proach may be of general use in different protein sys-
Overall, we have shown that peptide potency can betems where native protein crystals are not readily obtain-
regained after truncation of the p21WAF1 octapeptide andable, for example when contacts of surface-bound
that a molecule with a lower net charge can be obtainedligands with neighboring molecules are required for
through incorporation of unnatural amino acids. Thecrystallization.
structural basis for these improvements was rational-The peptides contain residues that are not directly
ized and suggests that the development of small mole-involved in binding but act as spacers and help to orient
cule inhibitors of the CDK2/CA via the substrate bindingthose groups involved in groove recognition. The
site is feasible. The important features of both the bind-charged amino terminus and side chain functions at P1
ing site and bound peptides incorporating nonnatural(Arg) are of prime importance for potency in the context
residues found during our work should facilitate the de-of pentapeptide inhibitors. Replacement of the charged
sign of more potent and less peptidic inhibitors.guanidine function with the uncharged isosteric urea
group (Cit) and acetylation of the N terminus lead to
Experimental Procedures36-fold and 3.8-fold potency reductions, respectively.
The importance of the P1-charged side chain is less
Expression and Purification of CDK2, Cyclin A,
pronounced in the octapeptide inhibitor series (McInnes and CDK2/CA Complex
et al., 2003), where the loss of the charge-charge interac- Human recombinant CDK2 was expressed and purified as described
(Wu et al., 2003). Human recombinant cyclin A2 (fragment encom-tion is partially offset by other favorable interactions
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passing residues 173–432) was expressed in Escherichia coli BL21 (Vagin and Teplyakov, 1997) and PDB entries 1HCL or 1CKP as the
search model. ARP/wARP (Lamzin and Wilson, 1997) was used for(DE3) using PET expression vectors. BL21 (DE3) was grown at 37	C
with shaking (200 rpm) to mid-log phase (A600nm  0.6). Expression initial density interpretation and the addition of water molecules.
REFMAC (Murshudov et al., 1997) was used for structural refine-was induced by the addition of IPTG at a final concentration of 1 mM
and the culture was incubated for a further 3 hr. Bacteria were ment. A number of rounds of refinement and model building with
the program Quanta (Accelrys, San Diego, USA) were carried out.harvested by centrifugation, and the cell pellet was resuspended in
buffer A (25 mM Tris [pH 8.0], 5 mM DTT, 1 mM PMSF, 1 mM EDTA,
1 mM benzamidine, and protease inhibitor cocktail). After sonication Computational Chemistry
Calculation of protein ligand interaction energies for the cyclin Athe lysate was clarified by centrifugation for 30 min at 15,000  g
and 4	C. The supernatant was passed through a DEAE-Sepharose inhibitors was performed using the program CDISCOVER after addi-
tion of hydrogens and steepest-descent minimization, using thecolumn (preequilibrated with buffer B: 25 mM Tris [pH 8.0], 2 mM
DTT, 1 mM PMSF, 1 mM EDTA, 1 mM benzamidine, and 10 mM modeling package InsightII (Accelrys, San Diego, USA).
NaCl). After washing, bound protein was eluted with an ascending
concentration gradient of NaCl in buffer B. The fractions containing Peptide Synthesis
Peptides were prepared, purified, and characterized using proce-cyclin A (typically eluted at 300–400 mM NaCl) were pooled, diluted
(5 times in buffer A without protease inhibitor cocktail), and loaded dures as previously described (Zheleva et al., 2002).
on to a preequilibrated (with buffer B) SP-Sepharose column. After
washing, bound protein was eluted with a NaCl gradient in buffer Biochemical Assays
These were carried out as previously described (Atkinson et al.,B. The fractions containing cyclin A (typically eluted at 300–400 mM
NaCl) were pooled, diluted (5 times in buffer A without protease 2002; McInnes et al., 2003; Zheleva et al., 2002).
inhibitor cocktail), and loaded on to a preequilibrated (with buffer
B) High-Trap Q column. After washing, bound protein was eluted Acknowledgments
with a NaCl gradient in buffer B. Pooled fractions containing pure
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Crystallization and Structure Determination
The CDK2/CA/peptide crystals were grown by vapor diffusion using
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